Microcarrier Cell Culture Patents: Leaders & Filing Trends 2026
- Concentrated but not locked up. the top 5 assignees hold 23.6% of all 611 records in scope, and the top 10 hold 37.6% — a real lead, but well short of a lockout.
- Filing has pulled back hard from its peak. annual filings fell from 40 in 2021 to 6 in 2024, an 85% drop over that three-year span, though 2025–2026 counts are still filling in as publications lag filing.
- Bioreactor apparatus claims trail biology claims by a wide margin. C12M (bioreactors & enzyme apparatus) appears in 26.8% of records versus 94.8% for C12N, suggesting hardware-side claims are comparatively less crowded.
Filing growth compares 2021 (40 records) with 2024 (6) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 611 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Microcarrier cell culture seed expansion sits at the intersection of adherent-cell biology and bioreactor engineering: the problem of moving a cell line from a small inoculum train to a commercial-scale culture without losing viability, doubling time, or seeding density control. This landscape draws on 611 published records filed or published between 2015 and mid-2026, indexed under IPC classes covering microorganisms and genetic engineering (C12N), bioreactor and enzyme apparatus (C12M), and cell culture vessels (C12M1/12), and filtered against language describing seeding density, passage number, viability thresholds, doubling time, inoculum trains and culture transitions.
Because a single family can generate several continuation or divisional filings, and because sponsors often file in more than one jurisdiction for the same invention, family-level counts are used throughout rather than raw document counts. That keeps concentration and trend figures comparable across assignees with different filing habits.
Filing trends and technology composition
The dataset spans a clear rise-and-fall filing cycle and a technology mix weighted heavily toward cell biology claims over apparatus claims.
A 2021 peak, then a steep pullback
Annual filings rose to a peak of 40 in 2021, then fell to 6 by 2024 — an 85% decline over that three-year window. Counts for 2025 and 2026 are still incomplete because publication typically lags filing by around 18 months, so the true trajectory for those years is not yet visible in this data.
Biology claims dominate; apparatus claims are thinner
C12N (microorganisms & genetic engineering) touches 94.8% of the 611 records, far ahead of C12M (bioreactors & enzyme apparatus) at 26.8% and A61K (medicinal preparations) at 19.5%. Sterilising methods (A61L, 7.0%) and enzyme/DNA testing (C12Q, 6.4%) trail further behind, indicating that most applicants are claiming the cultured cell product or process rather than the hardware that grows it.
Shares are the percentage of the 611 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Microcarrier Cell Culture Seed Expansion with Eureka
This page is one run against one query. Ask Eureka your own question about microcarrier cell culture seed expansion and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited prior art in this space
Seeding an adherent-cell bioreactor with non-adherent cells to raise seeding density and cut expansion time
This filing describes inoculating an adherent-cell bioreactor with suspension-adapted producer cells rather than the adherent form, a counter-intuitive route that the applicant states raises the achievable seeding density limit, shortens the delay between seeding and harvest, and reduces contamination risk during commercial-scale production of recombinant biological products.Filed by Ferring Ventures Ltd, published 2019-09-12 as US20190276846A1.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6642048B2 | Conditioned media for propagating human pluripotent stem cells | 438 |
| 2 | US20050106717A1 | Cell culture methods and devices utilizing gas permeable materials | 381 |
| 3 | US6458589B1 | Hepatocyte lineage cells derived from pluripotent stem cells | 360 |
| 4 | US5712163A | Chemically defined cell culture media and system and methods for use, particularly for culturing epithelial c… | 278 |
| 5 | US5266476A | Fibrous matrix for in vitro cell cultivation | 258 |
| 6 | US20060222634A1 | Amnion-derived cell compositions, methods of making and uses thereof | 190 |
| 7 | US6576464B2 | Methods for providing differentiated stem cells | 165 |
| 8 | WO2001081549A2 | Hepatocyte lineage cells derived from pluripotent stem cells | 162 |
| 9 | US20080166328A1 | In vitro expansion of postpartum-derived cells using microcarriers | 133 |
| 10 | US5155034A | Three-dimensional cell to tissue assembly process | 126 |
Citation counts inside a searched corpus favour older filings that have had more time to accumulate references — read them as a signal of influence on the field, not as a measure of current relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for a filing decision
Three patterns matter more than the raw counts: where claim density sits, how fast the field has cooled, and where the citation weight actually points.
A lead, not a lockout
The leading assignee holds 46 families and the fifth-ranked holds 19, but the top 5 combined still account for only 23.6% of the 611 records in scope, and the top 10 only 37.6%. That leaves the majority of filings spread across a long tail of single- or few-filing entrants — a structure that rewards a freedom-to-operate search over any assumption that the ground is already taken.
The filing wave has broken
Filings peaked at 40 in 2021 and had fallen to 6 by 2024, an 85% decline. That drop coincides with several of the most active historical filers showing zero filings in the latest tracked year, consistent with a technology area that saw a defined burst of activity rather than sustained year-on-year growth.
Influence sits with early stem-cell media patents
The most-cited records in this corpus — covering conditioned media, gas-permeable culture devices, and defined culture media — predate the seeding-density-specific language used in this search by years. Their high citation counts reflect foundational status in adherent and stem-cell culture generally, not that they are the most relevant art to a seeding-density or inoculum-train claim filed today.
Hardware claims are the thinner layer
C12N-classified biology and genetic-engineering claims touch 94.8% of records, while C12M bioreactor and enzyme-apparatus claims touch only 26.8%. For a team with a genuine hardware innovation — vessel geometry, agitation, in-line monitoring — that gap is worth checking directly rather than assuming the apparatus side is as crowded as the biology side.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to microcarrier cell culture seed expansion, with the prior art for and against each one.
The assignee landscape
One hundred assignees appear in the ranking this dataset returns. The leader holds 46 families; by fifth place that figure has fallen to 19, and by tenth place to 16 — a gradual taper rather than a cliff.
A single filer well ahead of the field
The top-ranked assignee holds 46 families against a fifth-place figure of 19, giving it more than double the next tier's output. Even so, that leader's share of the full 611-record set is a minority position, not a dominant one.
A broad second tier
Between fifth and tenth place, family counts move from 19 down to 16 — a shallow slope that points to several organisations filing at a comparable, steady pace rather than one runner-up closing the gap on the leader.
Most of the field is outside the ranked top 10
With the top 10 combined accounting for 37.6% of all 611 records, the remaining 62.4% is spread across the rest of the ranked assignees and unranked single-filers. That is where freedom-to-operate diligence needs to look hardest, since ownership there is fragmented and less predictable.
| Assignee | Recent year | YoY |
|---|---|---|
| Wilson Wolf Manufacturing Corp | 0 | — |
| Genzyme Corp | 0 | — |
| Baxter Healthcare SA | 0 | — |
| DePuy Synthes Products Inc | 0 | — |
| Novo Nordisk Health Care AG | 0 | — |
| President and Fellows of Harvard College | 0 | — |
| Schering Corp | 0 | — |
| Agency for Science, Technology and Research (A*STAR) | 0 | — |
Where to take this analysis
The numbers above frame the field; the next step is usually a targeted search against a specific claim or a specific competitor's portfolio.
Run a freedom-to-operate check on a specific route
The top 10 assignees hold well under half of all records in this space, so a general landscape view is not a substitute for checking a specific seeding, media, or apparatus claim against the full assignee list.
Search this claim in EurekaTrack momentum, not just historical share
Several of the largest historical filers show zero filings in the latest tracked year. Confirming whether that reflects a genuine pullback or a publication-lag gap needs a current search, not the 2021 peak figures.
Set up alerts in EurekaTest the under-claimed apparatus branches
With C12M apparatus claims touching a much smaller share of records than C12N biology claims, a hardware-focused idea may have more open ground than the field's overall filing volume suggests.
Explore white space in EurekaCommon questions about this landscape
Based on this 611-record dataset, one assignee leads with 46 families, well ahead of the fifth-ranked holder at 19 and the tenth-ranked holder at 16. Even so, the top 5 combined account for only 23.6% of all records in scope and the top 10 for 37.6%, so no single organisation or small group controls the field outright. A full assignee ranking of 100 companies is available for anyone doing detailed freedom-to-operate work, since most of the filing volume sits outside the top 10.
Filing volume peaked at 40 records in 2021 and had fallen to 6 by 2024, an 85% decline over that three-year span. That is the last year in this dataset that can be treated as complete, because publication typically lags filing by around 18 months, so 2025 and 2026 figures are still filling in. On the evidence available, the field has cooled substantially from its 2021 peak rather than continuing to expand.
This Ferring Ventures filing describes seeding an adherent-cell bioreactor with suspension-adapted, non-adherent producer cells instead of adherent cells, a method the applicant states raises the achievable seeding density limit and shortens the time between seeding and harvest. It is a process claim around how the bioreactor is inoculated, not a claim on the bioreactor hardware itself or on the cell line used. Anyone working on inoculation strategy for adherent-cell bioreactors should read the claim set directly rather than relying on the abstract, since the value of the invention is in the specific seeding method described.
The clearest gap in this dataset is between biology-side and apparatus-side claim density: C12N biology and genetic-engineering claims appear in 94.8% of the 611 records, while C12M bioreactor and apparatus claims appear in only 26.8%. That gap suggests specific apparatus mechanisms — in-line viability sensing, microcarrier detachment chemistry, closed-system transfer between inoculum train stages — carry comparatively less claim density than the underlying cell biology. It is not proof those areas are unclaimed, only that this search surfaces fewer apparatus-focused records relative to biology-focused ones.
The most-cited record in this corpus is US6642048B2, on conditioned media for propagating human pluripotent stem cells, cited 438 times, followed by patents on gas-permeable culture devices and defined cell culture media. These are older, foundational filings in adherent and stem-cell culture generally, and citation counts inside a searched corpus naturally favour older records that have had more years to accumulate references. High citation count signals historical influence on the field, not that a patent is the most relevant piece of prior art to check against a seeding-density or inoculum-train claim filed today.
Research Microcarrier Cell Culture Seed Expansion in depth with Eureka
Go past this page: query the whole microcarrier cell culture seed expansion corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.